HCA Gives $1 Million in Aid for Ebola Response

Primary Polycythemia

Definition

Polycythemia is a condition that occurs when the bone marrow produces an abnormal and excessive amount of red blood cells and platelets in the blood. The abnormal increase of red blood cells in the blood can cause the blood to thicken and clot.

There are several forms of polycythemia—primary polycythemia, secondary polycythemia, and stress polycythemia. Each form has its own set of causes and risk factors.

Location of Active Bone Marrow in an Adult
nucleus factsheet image
Copyright © Nucleus Medical Media, Inc.

Causes

Nearly all cases of primary polycythemia are believed to be caused by a mutation in the janus kinase 2 gene (JAK2).

Risk Factors

Factors that may increase your chances of developing primary polycythemia include:

  • Sex: male—twice as likely to be affected as women
  • Age: over the age of 40 years old; rarely are individuals under the age of 40 diagnosed with primary polycythemia
  • Race: Caucasians, Ashkenazi Jews

Symptoms

The symptoms of primary polycythemia occur gradually and vary from person to person. Some people show no signs of the condition. Symptoms may include:

  • Abnormal and heavy bleeding due to a cut or a nosebleed
  • Intense and frequent bone pain and/or muscle pain
  • Headaches, lightheadedness, or gastrointestinal symptoms
  • Vision problems
  • Ringing in the ears
  • Difficulty or labored breathing
  • The color of the skin appears reddish
  • Fatigue
  • Inability to concentrate
  • Intense itching after a warm or hot bath, shower, or any activity that requires soaking your skin in warm or hot water

Diagnosis

Your physician will ask about your symptoms and medical history. A physical exam will be done. You may also be referred to a doctor called a hematologist who specializes in blood diseases and disorders. The hematologist will perform a tests.

Your bodily fluids may be tested. This can be done with:

Treatment

Talk with your doctor about the best treatment plan for you. Treatment options include the following:

Phlebotomy

Phlebotomy is a technique that requires a person to periodically have blood removed from a vein to decrease the overall total proportion of red blood cells in the body. The frequency of the treatment is based on how quickly a person’s bone marrow produces an excessive amount of red blood cells.

Chemotherapy

Chemotherapy is a group of drugs that can be given by mouth, by injection, or through a tube that is inserted into a duct or blood vessel to slow the rapid development of red blood cells in the bone marrow.

Aspirin

You may be given aspirin to reduce your risk of blood clots and spleen removal.

Prevention

There are no known preventative measures that will reduce your chances of getting primary polycythemia; the condition is not contagious.

There is no cure, but recent research suggests that individuals who have primary polycythemia may significantly increase their overall life expectancy by seeking treatment right away.

Revision Information

  • American Society of Hematology

    http://www.hematology.org

  • The National Heart, Lung, and Blood Institute

    http://www.nhlbi.nih.gov

  • HealthLink BC

    http://www.healthlinkbc.ca

  • Capital Health Nova Scotia

    http://www.cdha.nshealth.ca

  • Berk PD, Goldberg JD, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132-143.

  • Gilbert HS. Current management in polycythemia vera. Semin Hematol. 2001;38(1 Suppl 2):25-28.

  • Golden C. Polycythemia vera: a review. Clin J Oncol Nurs. 2003;7:553-556.

  • Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Semin Hematol. 2004;41(2 Suppl 3):10-14.

  • Munson BL. Myths & facts…about polycythemia vera. Nursing. 2005;35:28.

  • Passamonti F, Rumi E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761.

  • Polycythemia vera. EBSCO DynaMed website. Available at: https://dynamed.ebscohost.com/about/about-us. Updated June 11, 2013. Accessed August 23, 2013.

  • Ruggeri M, Tosetto A, et al. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med. 2003;139:470-475.

  • Solberg LA Jr. Therapeutic options for essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29(3 Suppl 10):10-15.

  • Spivak JL. The optimal management of polycythaemia vera. Br J Haematol. 2002;116:243-254.

  • Stuart BJ, Viera AJ. Polycythemia vera. Am Fam Physician. 2004;69:2139-2144.

  • Tefferi A. A contemporary approach to the diagnosis and management of polycythemia vera. Curr Hematol Rep. 2003;2:237-241.

  • Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc. 2003;78:174-194.